However, a recent analysis of tumor biopsies from patients treated with olaparib on the TOPARP-B clinical trial found that loss of ATM protein expression by immunohistochemistry (IHC) was associated with longer PFS and overall survival than was observed in cases without ATM loss by IHC16,17. The gene discussed is ATM; the disease is neoplasm.